RsPSMA
RsPSMA Uses, Dosage, Side Effects, Food Interaction and all others data.
Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. RsPSMA is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). The vaccine comprises purified rsPSMA protein formulated with Alhydrogel® adjuvant. In preclinical studies, rsPSMA elicited high-titer antibodies that strongly cross-reacted with prostate cancer cells.
| Trade Name | RsPSMA |
| Generic | rsPSMA Vaccine |
| rsPSMA Vaccine Other Names | Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine, rsPSMA |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in prostate cancer.
How RsPSMA works
rsPSMA vaccine with Alhydrogel demonstrated safety and tolerability in addition to the induction of high-titer PSMA-specific antibodies (Abs) by ELISA with specificity directed to cell-surface, native PSMA as indicated by FACS analysis using cells expressing PSMA.
Like native, cell-surface PSMA, the rsPSMA protein was discovered to form a noncovalent dimer, and only the dimeric form of rsPSMA was enzymatically active and capable of inducing high levels of antibodies that cross-react with PSMA-expressing tumor cells. The findings provide important proof-of-concept for our rsPSMA vaccine
Innovators Monograph
You find simplified version here RsPSMA
